Radiotherapy & Oncology
Volume 90, Issue 1 , Pages 14-22 , January 2009

Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?

  • Mariella Mannino
    • ,
  • John R. Yarnold

      Affiliations

    • Corresponding Author InformationCorresponding author. Royal Marsden Hospital, Academic Radiotherapy Unit, Department of Clinical Oncology, Downs Road, Sutton, Surrey SM2 5PT, UK.

Received 10 March 2008 ,Accepted 1 May 2008.

References 

  1. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471
  2. Group TST, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371(9618):1098–107. Epub 2008 Mar 19.
  3. Group TST, The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331–41. Epub 2008 Mar 19.
  4. Cabioglu N, Hunt KK, Buchholz TA, et al. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005;104:20–29
  5. Pass H, Vicini FA, Kestin LL, et al. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Cancer. 2004;101:713–720
  6. Winzer KJ, Sauer R, Sauerbrei W, et al. Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2004;40:998–1005
  7. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–970
  8. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–977
  9. Potter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:334–340
  10. Blamey RW, Chetty U, Mitchell A. The BASO II trial of adjuvant radiotherapy. V. None and tamoxifen. V. None in small, node negative, grade I tumours. Eur J Cancer. 2002;38:S149
  11. Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112:758–766
  12. Ott OJ, Hildebrandt G, Potter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol. 2007;82:281–286
  13. Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma – 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702
  14. Winchester DP, Cox JD. Standards for breast-conservation treatment. CA Cancer J Clin. 1992;42:134–162
  15. Blichert-Toft M, Smola MG, Cataliotti L, et al. Principles and guidelines for surgeons – management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg Oncol. 1997;23:101–109
  16. Pierce LJ, Moughan J, White J, et al. 1998–1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I–II breast cancer. Int J Radiat Oncol Biol Phys. 2005;62:183–192
  17. Kingsmore D, Hole D, Gillis C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer. 2004;90:1920–1925
  18. Statement KSFFC. Consensus development conference: treatment of primary breast cancer. BMJ. 1986;946–947
  19. Borger J, Kemperman H, Hart A, et al. Risk factors in breast-conservation therapy. J Clin Oncol. 1994;12:653–660
  20. Pittinger TP, Maronian NC, Poulter CA, et al. Importance of margin status in outcome of breast-conserving surgery for carcinoma. Surgery. 1994;116:605–608[discussion 608–9]
  21. Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer. 1995;76:259–267
  22. Mansfield CM, Komarnicky LT, Schwartz GF, et al. Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer. 1995;75:2328–2336
  23. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al. Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys. 1998;40:851–858
  24. Freedman G, Fowble A, Hanlon A, et al. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys. 1999;44:1005–1015
  25. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18:1668–1675
  26. Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer. 2003;97:30–39
  27. Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer A. 1995;31A:1574–1579
  28. Schnitt SJ, Connolly JL, Khettry U, et al. Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer. 1987;59:675–681
  29. Fisher ER, Anderson S, Redmond C, et al. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8:161–166
  30. Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 1994;74:1746–1751
  31. Hurd TC, Sneige N, Allen PK, et al. Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy. Ann Surg Oncol. 1997;4:119–124
  32. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–1697
  33. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol. 2007;82:265–271
  34. Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17:2326–2333
  35. Renton SC, Gazet JC, Ford HT, et al. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol. 1996;22:17–22
  36. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339(8785): 71–85.
  37. Glick JH, Gelber RD, Goldhirsch A, et al., Adjuvant therapy of primary breast cancer. 4th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol 1992;3(10):801–7.
  38. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087–106.
  39. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7:991–996
  40. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570
  41. Hind D, Ward S, De Nigris E, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11:iii–ivix–xi, 1–134
  42. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  43. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492
  44. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–1853
  45. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA. 17. J Clin Oncol. 2007;25:2006–2011
  46. Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11:1–144
  47. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  48. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36
  49. Mitine C, Dutreix A, van der Schueren E. Tangential breast irradiation: influence of technique of set-up on transfer errors and reproducibility. Radiother Oncol. 1991;22:308–310
  50. Thilmann C, Adamietz IA, Saran F, et al. The use of a standardized positioning support cushion during daily routine of breast irradiation. Int J Radiat Oncol Biol Phys. 1998;41:459–463
  51. Lirette A, Pouliot J, Aubin M, et al. The role of electronic portal imaging in tangential breast irradiation: a prospective study. Radiother Oncol. 1995;37:241–245
  52. Truong PT, Berthelet E, Patenaude V, et al. Short communication: Setup variations in locoregional radiotherapy for breast cancer: an electronic portal imaging study. Br J Radiol. 2005;78:742–745
  53. Palazzi M, Tomatis S, Valli MC, et al. Impact of radiotherapy technique on the outcome of early breast cancer treated with conservative surgery: a multicenter observational study on 1,176 patients. Int J Radiat Oncol Biol Phys. 2006;65:1361–1367
  54. Denham JW, Carter ML, Gill PG. Conservative treatment of breast cancer–where should the booster dose go?. Int J Radiat Oncol Biol Phys. 1988;14:399–400
  55. Bedwinek J. Breast conserving surgery and irradiation: the importance of demarcating the excision cavity with surgical clips. Int J Radiat Oncol Biol Phys. 1993;26:675–679
  56. Harrington KJ, Harrison M, Bayle P, et al. Surgical clips in planning the electron boost in breast cancer: a qualitative and quantitative evaluation. Int J Radiat Oncol Biol Phys. 1996;34:579–584
  57. Regine WF, Ayyangar KM, Komarnicky LT, et al. Computer-CT planning of the electron boost in definitive breast irradiation. Int J Radiat Oncol Biol Phys. 1991;20:121–125
  58. Messer PM, Kirikuta IC, Bratengeier K, et al. CT planning of boost irradiation in radiotherapy of breast cancer after conservative surgery. Radiother Oncol. 1997;42:239–243
  59. Fein DA, Fowble BL, Hanlon AL, et al. Does the placement of surgical clips within the excision cavity influence local control for patients treated with breast-conserving surgery and irradiation. Int J Radiat Oncol Biol Phys. 1996;34:1009–1017
  60. Kokubo M, Mitsumori M, Yamamoto C, et al. Impact of boost irradiation with surgically placed radiopaque clips on local control in breast-conserving therapy. Breast Cancer. 2001;8:222–228
  61. NCIDCCPS, Surveillance, Epidemiology, and End Results (SEER) Program www.seer.cancer.gov. SEER Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. 2005.
  62. Statistics FIFoAR, Older Americans 2004: key indicators of well-being. Available at: http://www.agingstats.gov/chartbook2004/population.html.
  63. Smith BD, Gross CP, Smith GL, et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98:681–690
  64. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–556
  65. Molino A, Giovannini M, Auriemma A, et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol. 2006;59:226–233
  66. Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45:313–325
  67. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989;17:719–725
  68. Magee B, Swindell R, Harris M, et al. Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiother Oncol. 1996;39:223–227
  69. McCready DR, Chapman JA, Hanna WM, et al. Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients. Ann Surg Oncol. 2000;7:562–567
  70. Arriagada R, Le MG, Contesso G, et al. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002;13:1404–1413
  71. Clemente CG, Boracchi P, Andreola S, et al. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer. 1992;69:1396–1403
  72. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995;76:1772–1778
  73. Gurleyik G, Gurleyik E, Aker F, et al. Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer. Acta Chir Belg. 2007;107:284–287
  74. Sanghani M, Balk E, Cady B, et al. Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. Am J Clin Oncol. 2007;30:473–480
  75. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  76. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  77. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62
  78. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  79. Ford HT, Coombes RC, Gazet JC, et al. Long-term follow-up of a randomised trial designed to determine the need for irradiation following conservative surgery for the treatment of invasive breast cancer. Ann Oncol. 2006;17:401–408
  80. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88:1659–1664
  81. Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348:708–713
  82. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12:997–1003
  83. Fisher B, Bryant J, Dignam JJ, et al. J Clin Oncol. 2002;20:4141–4149
  84. Malmstrom P, Holmberg L, Anderson H, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003;39:1690–1697
  85. Holli K, Saaristo R, Isola J, et al. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer. 2001;84:164–169
  86. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  87. Prescott RJ, Kunkler IH, Williams LJ, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population The PRIME trial. Health Technol Assess. 2007;11:1–149iii–iv
  88. Hayman JA, Fairclough DL, Harris JR, et al. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol. 1997;15:1252–1260
  89. Schnitt SJ, Hayman J, Gelman R, et al. A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer. Cancer. 1996;77:100–1100

PII: S0167-8140(08)00239-9

doi: 10.1016/j.radonc.2008.05.002

Radiotherapy & Oncology
Volume 90, Issue 1 , Pages 14-22 , January 2009

Article Tools